Assessment | Biopsychology | Comparative | Cognitive | Developmental | Language | Individual differences | Personality | Philosophy | Social |
Methods | Statistics | Clinical | Educational | Industrial | Professional items | World psychology |

Biological: Behavioural genetics · Evolutionary psychology · Neuroanatomy · Neurochemistry · Neuroendocrinology · Neuroscience · Psychoneuroimmunology · Physiological Psychology · Psychopharmacology (Index, Outline)


3-Bromo-N-[ [(2S)-1-ethylpyrrolidin-2-yl]methyl]-2,6-dimethoxy-benzamide
IUPAC name
CAS number
ATC code


Chemical formula
Molecular weight 371.27 g/mol
Bioavailability C16H23BrN2O3
Elimination half-life
Pregnancy category
Legal status
Routes of administration

Remoxipride is a substituted benzamide which was a promising antipsychotic during clinical trials in the 1990s, but was removed due to possible side effects.

Clinical trials Edit

Remoxipride is a selective D2 antagonist, with a relatively low effective dosage and low incidence of side effects relative to haloperidol. However, after its introduction in Europe, its use was correlated with incidence of aplastic anemia in as many as 1 in 10,000 cases, and it was taken off the market until its relationship to this possible side effect could be studied.

External links Edit

This page uses Creative Commons Licensed content from Wikipedia (view authors).

Ad blocker interference detected!

Wikia is a free-to-use site that makes money from advertising. We have a modified experience for viewers using ad blockers

Wikia is not accessible if you’ve made further modifications. Remove the custom ad blocker rule(s) and the page will load as expected.